Revance Therapeutics, Inc. (RVNC): Kapitalflussrechnung Nicht notiert
Kennzahl in 1000 USD | TTM 2024-09-30 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Umsatz | 247.002,999 | 234.040 | 132.565 | 77.798 | 15.325 | 413 | 3.729 | 262 | 300 | 300 | 383 | 617 | 717 | 557 |
Cashflow aus operativer Geschäftstätigkeit | -190.887,999 | -216.575 | -193.548 | -221.538 | -178.502 | -106.161 | -104.246 | -95.342 | -59.827 | -55.669 | -55.073 | -47.758 | -38.914 | -28.413 |
▸ Operative Cashflow Marge | -77,28% | -92,54% | -146% | -284,76% | -1.164,78% | -25.704,84% | -2.795,55% | -36.390,08% | -19.942,33% | -18.556,33% | -14.379,37% | -7.740,36% | -5.427,34% | -5.101,08% |
Investitionsausgaben (CapEx) | 4.022 | 6.886 | 23.010 | 18.075 | 4.216 | 3.238 | 7.091 | 2.625 | 3.470 | 3.328 | 6.975 | 6.477 | 319 | 150 |
Cashflow aus Investitionstätigkeit | - | - | -138.798 | -29.665 | 12.131 | -17.592 | -107.026 | 118.792 | -75.499 | -56.340 | -6.900 | - | - | - |
Cashflow aus Finanzierungstätigkeit | 81.698 | 136.567 | 331.694 | 29.869 | 331.484 | 221.657 | 1.782 | 195.944 | -2.642 | 142.592 | 229.091 | 53.991 | 13.620 | 54.067 |
Freier Cashflow | -194.909,999 | -223.461 | -216.558 | -239.613 | -182.718 | -109.399 | -111.337 | -97.967 | -63.297 | -58.997 | -62.048 | -54.235 | -39.233 | -28.563 |
▸ Freie Cashflow Marge | -78,91% | -95,48% | -163,36% | -307,99% | -1.192,29% | -26.488,86% | -2.985,71% | -37.391,98% | -21.099% | -19.665,67% | -16.200,52% | -8.790,11% | -5.471,83% | -5.128,01% |
Ausgeschüttete Dividenden | - | - | -6.496 | - | -269.869 | - | - | - | - | - | - | - | - | - |
Neuausgabe und Rückkäufe von Stammaktien | -148 | -8.215,999 | -6.496 | -8.185 | -8.441 | -1.378 | -2.212 | -573 | -507 | -993 | 234.885 | - | - | - |
Kennzahlen dieser Seite im Lexikon
Weitere Informationen findest du im Takani-Lexikon.